Bone Fracture - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 84 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Bone Fracture - Pipeline Review, H1 2016

Summary

Global Markets Direct's, ‘Bone Fracture - Pipeline Review, H1 2016', provides an overview of the Bone Fracture pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Bone Fracture, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bone Fracture and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bone Fracture
- The report reviews pipeline therapeutics for Bone Fracture by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Bone Fracture therapeutics and enlists all their major and minor projects
- The report assesses Bone Fracture therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Bone Fracture

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Bone Fracture
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bone Fracture pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Content
Table of Contents 2

List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Bone Fracture Overview 9
Therapeutics Development 10
Pipeline Products for Bone Fracture - Overview 10
Pipeline Products for Bone Fracture - Comparative Analysis 11
Bone Fracture - Therapeutics under Development by Companies 12
Bone Fracture - Therapeutics under Investigation by Universities/Institutes 13
Bone Fracture - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Bone Fracture - Products under Development by Companies 16
Bone Fracture - Products under Investigation by Universities/Institutes 17
Bone Fracture - Companies Involved in Therapeutics Development 18
Arcarios BV 18
AstraZeneca Plc 19
Biogenomics Limited 20
BiologicsMD, Inc. 21
Biopharm GmbH 22
Bone Therapeutics SA 23
ethris GmbH 24
Juventas Therapeutics, Inc. 25
Kuros Biosciences AG 26
Novartis AG 27
TissueGene, Inc. 28
Viking Therapeutics, Inc. 29
Bone Fracture - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
ALLOB - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
AZD-2858 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
bimagrumab - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
BMD-1221 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Cyndacel-M - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
denosumab biosimilar - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
dibotermin alfa - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Drugs to Modulate Bone Morphogenetic Protein for Osteoarthritis and Fracture - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Drugs to Modulate PPAR-Delta for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Gene Therapy for Bone Fracture - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
JVS-200 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
KAL-436 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
KUR-111 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
KUR-113 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
LWnt-3a - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Oligonucleotide to Activate BMP-2 for Bone Fracture - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Recombinant Protein to Activate TNF-Alpha for Fracture Repair - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Small Molecules for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Small Molecules for Immunology, Musculoskeletal and Metabolic Disorders - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Stem Cell Therapy for Fracture Repair - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Synthetic Peptide for Osteoporosis and Bone Fracture - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
TG-B - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
VK-5211 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Bone Fracture - Recent Pipeline Updates 68
Bone Fracture - Dormant Projects 74
Bone Fracture - Discontinued Products 75
Bone Fracture - Product Development Milestones 76
Featured News & Press Releases 76
Nov 03, 2015: Viking Therapeutics Initiates Phase 2 Trial of VK5211 in Patients Recovering From Hip Fracture 76
Oct 20, 2015: Viking Therapeutics Completes Safety, Tolerability and Pharmacokinetic Study of VK5211, a Selective Androgen Receptor Modulator, in Healthy Elderly Subjects 76
Oct 09, 2015: Kuros Presents Results of Phase IIB Study with KUR-111 at the 2015 Orthopaedic Trauma Association Annual Meeting 77
Sep 01, 2015: Viking Therapeutics Initiates Clinical Trial for VK5211, a Selective Androgen Receptor Modulator, for Acute Hip Fracture 78
Jul 14, 2015: Viking Therapeutics Submits Investigational New Drug (IND) Application for VK5211, a Selective Androgen Receptor Modulator (SARM), in Acute Hip Fracture 78
Aug 29, 2013: Researcher Awarded $5 Million to Advance Future Stem Cell Treatments for Segmental Bone Fractures 79
Jan 24, 2011: Kuros Reports One Year Data From Phase IIb Study With KUR-111 80
Jun 02, 2010: Kuros Completes Patient Recruitment In A Phase IIB Trial Of KUR-113 In Patients With Tibial Shaft Fractures 81
Mar 15, 2010: Kuros Meets Primary Efficacy Endpoint In Phase IIb Study With KUR-111 81
Jun 08, 2009: Kuros Completes Patient Recruitment In A Phase IIb Trial Of KUR-111 In Patients With Tibial Plateau Fractures 82
Appendix 83
Methodology 83
Coverage 83
Secondary Research 83
Primary Research 83
Expert Panel Validation 83
Contact Us 83
Disclaimer 84

List of Tables

Number of Products under Development for Bone Fracture, H1 2016 10
Number of Products under Development for Bone Fracture - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Development, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Investigation by Universities/Institutes, H1 2016 17
Bone Fracture - Pipeline by Arcarios BV, H1 2016 18
Bone Fracture - Pipeline by AstraZeneca Plc, H1 2016 19
Bone Fracture - Pipeline by Biogenomics Limited, H1 2016 20
Bone Fracture - Pipeline by BiologicsMD, Inc., H1 2016 21
Bone Fracture - Pipeline by Biopharm GmbH, H1 2016 22
Bone Fracture - Pipeline by Bone Therapeutics SA, H1 2016 23
Bone Fracture - Pipeline by ethris GmbH, H1 2016 24
Bone Fracture - Pipeline by Juventas Therapeutics, Inc., H1 2016 25
Bone Fracture - Pipeline by Kuros Biosciences AG, H1 2016 26
Bone Fracture - Pipeline by Novartis AG, H1 2016 27
Bone Fracture - Pipeline by TissueGene, Inc., H1 2016 28
Bone Fracture - Pipeline by Viking Therapeutics, Inc., H1 2016 29
Assessment by Monotherapy Products, H1 2016 30
Number of Products by Stage and Target, H1 2016 32
Number of Products by Stage and Mechanism of Action, H1 2016 34
Number of Products by Stage and Route of Administration, H1 2016 36
Number of Products by Stage and Molecule Type, H1 2016 38
Bone Fracture Therapeutics - Recent Pipeline Updates, H1 2016 68
Bone Fracture - Dormant Projects, H1 2016 74
Bone Fracture - Discontinued Products, H1 2016 75